Halozyme Therapeutics (HALO) Operating Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Operating Expenses data on file, last reported at $192.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $192.2 million, up 55.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $996.5 million (up 104.68% YoY), and the FY2025 annual result was $927.6 million, up 99.98% from the prior year.
• Operating Expenses retreated to $192.2 million in Q1 2026 per HALO's latest filing, from $544.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $544.7 million in Q4 2025 and troughed at $41.6 million in Q1 2022.
• A 5-year average of $145.2 million and a median of $123.3 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses fell 9.85% in 2024, then surged 344.59% in 2025.
• A 5-year view of Operating Expenses shows it stood at $107.0 million in 2022, then grew by 20.58% to $129.0 million in 2023, then retreated by 5.04% to $122.5 million in 2024, then jumped by 344.59% to $544.7 million in 2025, then tumbled by 64.71% to $192.2 million in 2026.
• Business Quant data shows HALO's Operating Expenses at $192.2 million in Q1 2026, $544.7 million in Q4 2025, and $136.3 million in Q3 2025.